Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Geen effecten gevonden.

Nieuws over “Biotechnologie”

03:30 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

03:30 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

1/05 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1/05 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1/05 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

1/05 · KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS · Persbericht

1/05 · Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates · Persbericht

1/05 · REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights · Persbericht

1/05 · AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 · Persbericht

1/05 · Alkermes plc Reports First Quarter 2024 Financial Results · Persbericht

1/05 · Neurocrine Biosciences Reports First Quarter 2024 Financial Results · Persbericht

1/05 · Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 · Persbericht

1/05 · BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS · Persbericht

1/05 · BIO-TECHNE DECLARES DIVIDEND · Persbericht

1/05 · IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event · Persbericht

1/05 · Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Corporation Lawsuit - AVXL · Persbericht

30/04 · Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules · Persbericht

30/04 · Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 · Persbericht

30/04 · 10x Genomics Reports First Quarter 2024 Financial Results · Persbericht

30/04 · Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 · Persbericht

30/04 · Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024 · Persbericht

Mijn selecties